Attendee search 

PHASTAR is a specialist biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents. PHASTAR is also currently in the process of setting up an office in Shangai, China. 

New VC focused on biotech

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.

To find out more, contact us at partnerships@bios.health.

CareAcross is a cancer-focused digital health company. Our offerings include personalized digital therapeutics via engaging online platforms. Our business services include real-world evidence, patient engagement & monitoring programs, & clinical trial recruitment.

Our clients include, among others, most of the top biopharma companies in oncology, medical devices companies, diagnostics providers, etc.  Our business services are primarily based on our core assets: direct access to patients, and access to & ownership of patient data. While our focus has been in the cancer therapeutic area through our deep expertise and network, our technology is applicable to any long term or chronic condition, and enables patient engagement and improved outcomes.

Among the outcomes we can share are:

• reduced incidence of side-effects by 11%
• 5x reduction in risk of cancer malnutrition
• 65% increase in physical activity
• 68% improved patient engagement.

The approach is based on scientific evidence & guidelines: CareAcross experts process peer-reviewed journal articles on a daily basis (the company has already analysed several thousands of such articles). The applicable ones are “translated” to lay terms by experienced content writers, continuously updating the content library. The library consists of text, visuals & videos, and currently contains >500,000 words of original, patient-friendly content.
The material is selected based on each patient’s needs as entered in brief questionnaires (built entirely dynamically): advanced dynamic algorithms match each patient’s situation & needs with the right material from the content library. The level of personalisation is so deep that there are modules offering >20,000 different material combinations; the algorithms identify the most relevant for each individual patient.

Additionally, clinicians can monitor patients' progress remotely, and unobtrusively, with intuitive graphs and ongoing data collection.

The current focus areas include comorbidities, side-effects, nutrition, exercise, weight control, emotional wellbeing, and more. Furthermore, and in order to cultivate long-term engagement, CareAcross employs various methodologies including personalised newsletters, notifications, quantified-self techniques with intuitive scores & graphs, and others.
As a result, CareAcross delivers long-term, engaging, personalised coaching services to cancer patients, via material which is always available to them.
The approach does not aim to replace patients’ healthcare teams and clinicians, but to support patients in the majority of their time (95% on average) which they spend outside the clinic.

Our Patient Operations are active in several countries and continents.

Our Chief Medical Officer is a medical oncologist, and has been a president of the European Society for Medical Oncology (ESMO), among others. Our Chief Executive Officer is a member of the Assembly of the European Commission's Cancer Mission.

We have been awarded 3 grants by the European Commission on Big Data and Artificial Intelligence in Cancer enabling international collaborations with established centers of excellence.

We have been profitable in the last 4 accounting periods.